The advantage of using a broadly expressed antigen such as SPN, whose expression is also maintained in most blood-cancer-derived cell lines, is to not only address relapse in AML but also potentially extend the product to patients with other blood cancers. This evidence concerns the gene SPN and hematopoietic and lymphoid system neoplasm.